User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Ecteinascidin-743: Evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients

Primary tabs

download
  • Open access
  • PDF
  • 1.37 M
Huygh, G. Clement, Paul M. J. Dumez, H. Schöffski, P. Wildiers, H. Duck, Lionel [UCL] Van Oosterom, A.T.

Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900-1500 μg/ m2 every 3 weeks. Results. We observed one complete remission, 5 partial remissions, one minimal response, and 16 patients with a disease stabilization of 6 months or more. The objective response rate was 6.7% and the clinical benefit rate at 3 and 6 months was 37.7% and 23.4%, respectively. Responses were noted in patients with lipo-, leiomyo-, osteo-, and myogenic sarcoma, with a median duration of 9.85 months. Toxicity mainly involved an asymptomatic elevation of transaminases and neutropenia. Estimated 1- and 2-year survival rates were 39.4% and 15.8%. Median overall survival was 8.25 months. Discussion. This retrospective analysis confirms that ET-743 induces objective responses and progression arrest in a clinically relevant proportion of patients. Copyright © 2006 G. Huygh et al.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2006
Language Anglais
Journal information "Sarcoma" - Vol. 2006 (2006)
Peer reviewed yes
Publisher Hindawi Publishing Corporation
e-issn 1369-1643
issn 1357-714X
Publication status Publié
Affiliation UCL - (SLuc) Unité d'oncologie médicale
Links
  1. CA: A Cancer Journal for Clinicians, 50, 7 (2000)
  2. Pisters P W, Leung D H, Woodruff J, Shi W, Brennan M F, Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities., 10.1200/jco.1996.14.5.1679
  3. Spira A. I., The Use of Chemotherapy in Soft-Tissue Sarcomas, 10.1634/theoncologist.7-4-348
  4. van Oosterom A.T, Mouridsen H.T, Nielsen O.S, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J, Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients, 10.1016/s0959-8049(02)00491-4
  5. Yovine A., Riofrio M., Blay J.Y., Brain E., Alexandre J., Kahatt C., Taamma A., Jimeno J., Martin C., Salhi Y., Cvitkovic E., Misset J.L., Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients, 10.1200/jco.2004.05.210
  6. Van Glabbeke M., van Oosterom A.T., Oosterhuis J.W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T., Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study, 10.1200/jco.1999.17.1.150
  7. Blay J-Y, van Glabbeke M, Verweij J, van Oosterom A.T, Le Cesne A, Oosterhuis J.W, Judson I, Nielsen O.S, Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy, 10.1016/s0959-8049(02)00480-x
  8. Journal of Biomolecular Structure and Dynamics, 10, 793 (1993)
  9. Zewail-Foote Maha, Hurley Laurence H., Ecteinascidin 743:  A Minor Groove Alkylator That Bends DNA toward the Major Groove, 10.1021/jm990241l
  10. Pommier Yves, Kohlhagen Glenda, Bailly Christian, Waring Michael, Mazumder Abhijit, Kohn Kurt W., DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean TunicateEcteinascidia turbinata, 10.1021/bi960306b
  11. Jin S., Gorfajn B., Faircloth G., Scotto K. W., Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation, 10.1073/pnas.97.12.6775
  12. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., Mantovani R., Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743, 10.1073/pnas.97.12.6780
  13. Takebayashi Yuji, Pourquier Philippe, Zimonjic Drazen B., Nakayama Kentaro, Emmert Steffen, Ueda Takahiro, Urasaki Yoshimasa, Kanzaki Atsuko, Akiyama Shin-ichi, Popescu Nicholas, Kraemer Kenneth H., Pommier Yves, 10.1038/91008
  14. Clinical Cancer Research, 7, 2908 (2001)
  15. Gajate Consuelo, An Feiyun, Mollinedo Faustino, Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells : TRANSCRIPTION-DEPENDENT CELL CYCLE ARREST AND TRANSCRIPTION-INDEPENDENT JNK AND MITOCHONDRIAL MEDIATED APOPTOSIS, 10.1074/jbc.m204644200
  16. Annals of Oncology, 5, 185 (1994)
  17. Hendriks H. R., Fiebig H. H., Giavazzi R., Langdon S. P., Jimeno J. M., Faircloth G. T., High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer, 10.1023/a:1008364727071
  18. Izbicka E., Lawrence R., Raymond E., Eckhardt G., Faircloth G., Jimeno J., Clark G., Von Hoff D. D., In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients, 10.1023/a:1008224322396
  19. Clinical Cancer Research, 4, 1977 (1998)
  20. Clinical Cancer Research, 8, 75 (2002)
  21. Delaloge S., Yovine A., Taamma A., Riofrio M., Brain E., Raymond E., Cottu P., Goldwasser F., Jimeno J., Misset J. L., Marty M., Cvitkovic E., Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity, 10.1200/jco.2001.19.5.1248
  22. Taamma A., Misset J. L., Riofrio M., Guzman C., Brain E., Lopez Lazaro L., Rosing H., Jimeno J. M., Cvitkovic E., Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors, 10.1200/jco.2001.19.5.1256
  23. Clinical Cancer Research, 7, 231 (2001)
  24. van Kesteren Charlotte, Twelves Chris, Bowman Angela, Hoekman Klaas, López-Lázaro Luis, Jimeno José, Guzman Cecilia, Mathôt Ron AA, Simpson Andrew, Vermorken Jan B, Smyth John, Schellens Jan HM, Hillebrand Michel JX, Rosing Hilde, Beijnen Jos H, Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study : , 10.1097/00001813-200204000-00007
  25. Bramwell Vivien H.C., Mouridsen H.T., Santoro A., Blackledge G., Somers R., Verwey J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R., Van Oosterom A., Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas, 10.1016/0277-5379(87)90075-7
  26. Verweij J., Mouridsen H.T., Nielssen O.S., Woll P.J., Somers R., van Oosterom A.T., Van Glabbeke M., Tursz T., The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view, 10.1016/1040-8428(94)00146-k
  27. Nielsen O.S., Judson I., van Hoesel Q., le Cesne A., Keizer H.J., Blay J.Y., van Oosterom A., Radford J.A., Svancárová L., Krzemienlecki K., Hermans C., van Glabbeke M., Oosterhuis J.W., Verweij J., Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group, 10.1016/s0959-8049(99)00240-3
  28. Steward W P, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group., 10.1200/jco.1993.11.1.15
  29. Patel S R, Vadhan-Raj S, Papadopolous N, Plager C, Burgess M A, Hays C, Benjamin R S, High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence., 10.1200/jco.1997.15.6.2378
  30. Antman K H, Ryan L, Elias A, Sherman D, Grier H E, Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma., 10.1200/jco.1989.7.1.126
  31. Palumbo R., Palmeri S., Antimi M., Gatti C., Raffo P., Villani G., Toma S., Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas, 10.1023/a:1008279426654
  32. Le Cesne A., Judson I., Crowther D., Rodenhuis S., Keizer H.J., Van Hoesel Q., Blay J.Y., Frisch J., Van Glabbeke M., Hermans C., Van Oosterom A., Tursz T., Verweij J., Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, 10.1200/jco.2000.18.14.2676
  33. Garcia-Carbonero R., Supko J.G., Manola J., Seiden M.V., Harmon D., Ryan D.P., Quigley M.T., Merriam P., Canniff J., Goss G., Matulonis U., Maki R.G., Lopez T., Puchalski T.A., Sancho M.A., Gomez J., Guzman C., Jimeno J., Demetri G.D., Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy, 10.1200/jco.2004.02.098
  34. Proceedings of the American Society for Clinical Oncology, 21, 408a (2002)
  35. Ferguson William S., Goorin Allen M., Current Treatment of Osteosarcoma, 10.1081/cnv-100102557
  36. Le Cesne A., Blay J.Y., Judson I., Van Oosterom A., Verweij J., Radford J., Lorigan P., Rodenhuis S., Ray-Coquard I., Bonvalot S., Collin F., Jimeno J., Di Paola E., Van Glabbeke M., Nielsen O.S., Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial, 10.1200/jco.2005.01.180
  37. Van Glabbeke M, Verweij J, Judson I, Nielsen O.S, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas, 10.1016/s0959-8049(01)00398-7
  38. Proceedings of the American Society for Clinical Oncology, 20, 352a (2000)
  39. Proceedings of the American Society for Clinical Oncology, 21, 96a (2002)
  40. Proceedings of the American Society for Clinical Oncology, 19, 187a (2000)
Bibliographic reference Huygh, G. ; Clement, Paul M. J. ; Dumez, H. ; Schöffski, P. ; Wildiers, H. ; et. al. Ecteinascidin-743: Evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. In: Sarcoma, Vol. 2006 (2006)
Permanent URL http://hdl.handle.net/2078.1/164686